| 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. | |
| | |
MedLine Citation:
|
PMID: 11169064 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: The aim of this paper is to describe the imaging pattern of focal nodular hyperplasia (FNH) by l8F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET). METHODS: Eight consecutive asymptomatic patients with histologic proof of FNH underwent 18F-FDG PET imaging. The lesions were found incidentally. The 18F-FDG PET imaging was performed with a dedicated PET tomograph after intravenous injection of 300-370 MBq 18F-FDG. The 18F-FDG accumulation in the lesions was (semi)quantified by calculating the standardized uptake value (SUV) and SUV has been corrected for the lean body mass (LBM). Eight patients with liver metastases spread from melanoma (n=2) and colorectal carcinoma (n=6) served as controls. The size of the FNH lesions and of the control group ranged from 2.0 to 8.5 cm (mean 4.83 cm +/- 2.37) and from 1.5 to 6 cm (mean 3.28 +/- 1.52), respectively. RESULTS: While in malignant liver lesions the accumulation of 18F-FDG was significantly increased, all FNH lesions showed normal or even decreased accumulation of 18F-FDG. In FNH lesions, SUV ranged between 1.5 and 2.6 (mean 2.12 +/- 0.38), whereas all liver metastases showed an increased SUV ranging between 6.20 and 16.00 (mean 10.07 +/- 3.79). The SUV corrected for LMB (SUVLBM) was similar to the SUV and ranged between 0.9 and 2.2 (mean 1.81 +/- 0.41) for FNH and between 5.9 and 16.3 (mean 9.15 +/- 4.03), respectively. CONCLUSION: In contrast to liver metastases, there is no increased glucose metabolism in FNH in vivo. The imaging feature of FNH by 18F-FDG-PET imaging is not specific for FNH; however, it may be helpful to differentiate FNH from liver metastases in cancer patients if radiological methods are not diagnostic. |
| | |
Authors:
|
A Kurtaran; A Becherer; F Pfeffel; C Müller; T Traub; J Schmaljohann; K Kaserer; M Raderer; W Schima; R Dudczak; K Kletter; I Virgolini |
Related Documents
:
|
15382304 - Current state of imaging for lung cancer staging. 16619274 - Pet-ct vs contrast-enhanced ct: what is the role for each after chemoradiation for adva... 19585114 - Efficacy of 18f-fdg pet/ct in the evaluation of patients with recurrent cervical carcin... 20458484 - Imaging of advanced renal cell carcinoma. 3553114 - Prospective comparison of ultrasound and computed tomography in the evaluation of the s... 10505884 - Treatment planning considerations and quality assurance for ct-guided transischiorectal... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver Volume: 20 ISSN: 0106-9543 ISO Abbreviation: Liver Publication Date: 2000 Dec |
Date Detail:
|
Created Date: 2001-01-19 Completed Date: 2001-03-08 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8200939 Medline TA: Liver Country: Denmark |
Other Details:
|
Languages: eng Pagination: 487-90 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, University of Vienna, Austria. amir.kurtaran@akh-wien.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Fluorodeoxyglucose F18 / administration & dosage, diagnostic use* Focal Nodular Hyperplasia / pathology, radionuclide imaging* Humans Injections, Intravenous Liver Neoplasms / radionuclide imaging, secondary Male Middle Aged Radiopharmaceuticals / administration & dosage, diagnostic use* Tomography, Emission-Computed* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heterozygosity for the hemochromatosis gene in liver diseases--prevalence and effects on liver histo...
Next Document: Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of ...